Amonafide L-malate: Completed Phase III enrollment

Antisoma completed enrollment of over 420 patients in the open-label, international Phase III ACCEDE trial comparing 600 mg/m 2 IV AS1413 given for 5 days plus cytarabine vs. daunorubicin plus cytarab...